drugset / Trial / NCT00947791

Treatment Study of Bipolar Depression

NCT00947791

Phase 4 Terminated 1 enrolled Icahn School of Medicine at Mount Sinai
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to determine whether a single intravenous administration of an N-methyl-D-aspartate antagonist is safe and effective for the acute treatment of bipolar depression.

Timeline

Start
2009-07
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.5 mg/kg Intravenous
Subject Midazolam Small molecule 0.045 mg/kg Intravenous

Indications